No Prescription Meds

No Prescription Meds - Buy Online
HomeAlpha IndexCategories

Bookmark and Share

Prescription Meds - A

Prescription Meds - B

Prescription Meds - C

Prescription Meds - D

Prescription Meds - E

Prescription Meds - F

Prescription Meds - G

Prescription Meds - H

Prescription Meds - I

Prescription Meds - J

Prescription Meds - K

Prescription Meds - L

Prescription Meds - M

Prescription Meds - N

Prescription Meds - O

Prescription Meds - P

Prescription Meds - Q

Prescription Meds - R

Prescription Meds - S

Prescription Meds - T

Prescription Meds - U

Prescription Meds - V

Prescription Meds - W

Prescription Meds - X

Prescription Meds - Y

Prescription Meds - Z

Prescription Meds - 0-9

Home

Product Index

Category List

Dantrium Generic Dantrolene

Home » Prescription Drugs 5 » Dantrium Generic Dantrolene

IndicationsDANTRIUM is indicated in controlling the manifestations of clinical spasticity resulting from serious chronic disorders such as spinal cord injury stroke cerebral palsy or multiple sclerosis. It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. There is no evidence that patients with contractures will benefit. DANTRIUM is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders or electroconvulsive therapy.If improvement occurs it will ordinarily occur within the dosage titration schedule (see DOSAGE AND ADMINISTRATION) as manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without DANTRIUM.Occasionally subtle but meaningful improvements in spasticity may occur with DANTRIUM therapy. In such instances information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of DANTRIUM for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestation of spasticity and may serve to confirm a clinical impression.A decision to continue the administration of DANTRIUM on a long term basis is justified if introduction of the drug into the patient's regimen produces a significant reduction in painful and/or disabling spasticity such as clonus or permits a significant reduction in the intensity and/or degree of nursing care required or rids the patient of an annoying manifestation of spasticity considered important by the patient himself.Dosage and Administration:Prior to the administration of DANTRIUM consideration should be given to the potential response to treatment. A decrease in spasticity sufficient to allow a daily function not otherwise attainable should be the therapeutic goal of treatment with DANTRIUM. Refer to the INDICATIONS section for a description of the response to be anticipated.It is important to establish a therapeutic goal (regain and maintain a specific function such as therapeutic exercise program utilisation of braces transfer manoeuvres etc.) before beginning DANTRIUM therapy. Dosage should be increased until the maximum performance compatible with the dysfunction due to underlying disease is achieved. No further increase in dosage is then indicated.Usual Dosage It is important that the dosage be titrated and individualised for maximum effect. The lowest dose compatible with optimal response is recommended.In view of the potential for liver damage in long-term DANTRIUM use therapy should be stopped if benefits are not evident within 45 days.Adults Begin therapy with 25 mg once daily; increase to 25 mg two three or four times daily and then by increments of 25 mg up to as high as 50 mg two three or four times daily if necessary. The maximum recommended dose is 200 mg/day. As most patients will respond to this or a lower dose and hepatotoxicity appears to be dose-related above 200 mg/day higher doses should be used only rarely and with close monitoring. (See WARNINGS). Doses higher than 400 mg/day should not be used.Each dosage level should be maintained for four to seven days to determine the patient's response. The dose should not be increased beyond and may even have to be reduced to the amount at which the patient received maximal benefit without adverse effects.Children A similar approach should be utilised starting with 0.5 mg/kg of body weight twice daily; this is increased to 0.5 mg/kg three or four times daily and then by increments to a maximum of 2 mg/kg three times a day. Doses higher than 50 mg four times daily should not be used in children.

Buy Dantrium Generic Dantrolene and other Prescription Drugs 5 products online at Medstore.

Buy Online at Medstore - Click Here!

About Dantrium Generic Dantrolene:

Product Type: Prescription Drugs 5

Dantrium ( Generic Dantrolene )

Dantrium (Generic Dantrolene)

Generic Dantrolene

25mg 100 Capsules 50mg 100 Capsules Generic Dantrolene Dantrium

View more Prescription Drugs 5

Previous Product  Next Product

You do not need a prescription to buy our products as we work under the laws of the country we ship from. We do recommend you check with your local customs to see if it is okay to import these products. Errors and Omissions. We are not responsible for any typographical errors or inaccuracies set forth in this website. The information, prices, and discounts set forth herein are subject to change without notice. Product Fulfilment : The pharmacy / Fulfilment Centre cannot be held liable for the accuracy of the diagnosis, treatment or medication prescribed or the correct use of products supplied. It lies on the purchaser to use any products supplied under the guidance of a physician. Product Quality. The Pharmacy / Fulfilment Centre is responsible for ensuring that the correct product, in the correct amount and the correct strength is supplied to the correct patient. Product liability lies solely with the manufacturer.
 
World Drug News. Government funding crisis in Swaziland disrupts supply of HIV/AIDS supplies. "An acute government funding crisis in Swaziland, Africa's last absolute monarchy, is disrupting supplies of HIV/AIDS drugs and hampering the fight against the virus in the country with the world's highest infection rate, Medecins Sans Frontieres (MSF) said Friday," Reuters reports. "Stocks of testing kits and related chemicals were 'almost dry,' making it next-to-impossible to chart the progress of the 70,000 patients on therapy or more than 130,000 other people carrying the virus, the aid agency said," according to Reuters. "With 26 percent of its adult population, or more than 200,000 people infected, Swaziland ranks as the most AIDS-affected country," Reuters writes (Cropley, (9/9). In related news, a new report from Swaziland's government "has found that more than half of [30,000 Swazis, mostly women, working] in Swaziland's garment industry are living with HIV, and officials are realizing that the once-hailed promise of manufacturing employment has become a financial and medical nightmare for tens of thousands of Swazi women," PlusNews reports (8/11). This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
 
Glez Glucotrol 
Gliben Daonil 
Gliclazide Glyade 
Glimax Amaryl 
Glimy Amaryl 
GLINATE Starlix 
Glinil M Glucovance 
GlucoBalance 
Glucobay Precose 
Glucophage Fortamet 
Glucophage (Metformin) 
Glucotrol (Glipizide SR) 
Glucotrol XL Generic Glipizide 
Glucovance Generic Glyburide 
GLUMET Glucophage 
Glynase Glucotrol 
Glynase XL Glucotrol XL 
Gonaphene Clomid 
GRANICIP KYTRIL 
Graniset Kytril 
Grief & Pining Formula 
Grisactin (Griseofulvin) 
GRISOVIN Fulvicin